This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Santarus, Inc.
Santarus, Inc., a prominent biopharmaceutical company headquartered in the United States, has established itself as a leader in the development of innovative therapies for gastrointestinal and rare diseases. Founded in 2003, Santarus has achieved significant milestones, including the successful launch of several FDA-approved products that address unmet medical needs. The company focuses on specialised areas such as inflammatory bowel disease and other gastrointestinal disorders, offering unique formulations that enhance patient compliance and treatment outcomes. Santarus is recognised for its commitment to research and development, positioning itself strongly within the biopharmaceutical industry. With a robust portfolio of core products, Santarus continues to make strides in improving the quality of life for patients worldwide.
DitchCarbon Score
How does Santarus, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Santarus, Inc.'s score of 40 is higher than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Santarus, Inc., headquartered in the US, currently does not report specific carbon emissions data, as there are no available figures for emissions in kg CO2e. The company is a current subsidiary of Bausch Health Companies Inc., which may influence its climate commitments and reporting practices. While Santarus, Inc. does not have its own documented reduction targets, it inherits climate initiatives from its parent company, Bausch Health Companies Inc. This includes commitments to the Science Based Targets initiative (SBTi) and participation in the Carbon Disclosure Project (CDP). These initiatives aim to align corporate strategies with climate science and enhance transparency regarding environmental impact. As a subsidiary, Santarus may benefit from Bausch Health's broader sustainability goals, although specific targets or achievements at the Santarus level remain unspecified. The absence of direct emissions data highlights the need for further clarity on the company's individual climate commitments and performance.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 46,686,000 | 00,000,000 |
| Scope 2 | 50,513,000 | 00,000,000 |
| Scope 3 | 19,260,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Santarus, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
